Personalised Management of Prostate Cancer
Despite recent advances, prostate cancer continues to be a leading cause of cancer-related death among men. While the standard management options of surgery, radiotherapy, and androgen deprivation therapy are well established, there are still significant unmet needs. For example, which patients woul...
Main Authors: | Dilip Babu, Deepak Sahasrabudhe |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2018-06-01
|
Series: | European Medical Journal Urology |
Subjects: | |
Online Access: | https://www.emjreviews.com/urology/article/personalised-management-of-prostate-cancer/ |
Similar Items
-
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
by: Andrew D. Simmons, et al.
Published: (2020-03-01) -
Preparation and Characterization of Model Conjugates for the Study of Proteins Modified by ADP-ribose
by: Cervantes-Laurean, Daniel
Published: (1992) -
Structurally unique PARP‐1 inhibitors for the treatment of prostate cancer
by: Ali Divan, et al.
Published: (2020-04-01) -
Expression of PARP-1 in ovarian cancer tissue before and after chemotherapy and its correlation with cellular epithelial mesenchymal transition
by: Xiao-Zhen Wang1, et al.
Published: (2017-05-01) -
Studies on Poly (ADP-ribose) Synthesis in Lymphocytes of Systemic Lupus Erythematosus Patients
by: Chen, Hai-Ying
Published: (1991)